BigHat Biosciences

BigHat Biosciences designs safer, more effective antibody therapies using machine learning and synthetic biology. The company's Milliner platform integrates a synthetic biology-based high-speed wet lab with state-of-the-art machine learning technologies into a full-stack antibody discovery and engineering platform. Hundreds of recombinant antibodies can be synthesized, purified, and fully characterized for biophysics and function in a single weekly workcell. BigHat applies these capabilities to develop next-generation treatments for patients suffering from today's most challenging diseases, including cancers and infections, targeting greater safety and efficacy through rational molecular design. The company has formed strategic collaborations with AbbVie, Johnson & Johnson, and Lilly, and has raised over $100M from top investors to pursue its vision.